Overview

Cryo-Cell International, Inc. (“Cryo-Cell” or “the Company”) has released its Annual Report on Form 10-K for the fiscal year ended November 30, 2025. This comprehensive filing offers a deep dive into the Company’s financial and operational performance, risk factors, and strategic outlook. Here are the most crucial details for shareholders and potential investors.

Key Highlights

• Common Stock Details: The Company’s common stock is traded on the NYSE American LLC under the symbol CCEL.
• Market Capitalization: As of May 31, 2025, the aggregate market value of Common Stock held by non-affiliates was \$26,519,624.
• Shares Outstanding: As of February 28, 2026, there were 8,055,150 shares of Common Stock outstanding.
• Status: The Company is a “smaller reporting company” and not an emerging growth company.

Potentially Price-Sensitive Issues for Shareholders

• NYSE American Listing Risk:

  The report highlights a significant risk: Cryo-Cell may be delisted from NYSE American LLC if it fails to meet continued listing standards. These standards include corporate governance requirements and other financial benchmarks. Delisting would likely depress the stock price, severely limit liquidity, and restrict the Company’s ability to raise additional capital. Reduced analyst coverage and news media attention could further pressure the share price, and disposal of shares may become more difficult for investors.

• Need for Additional Capital:

  The Company states that while current cash, cash equivalents, marketable securities, and operating cash flows should be sufficient for the next 12 months, additional financing may be required. If expected revenues do not materialize or costs exceed expectations, Cryo-Cell may need to cut or defer expenditures, which could adversely affect business operations, sales, and development of new services. Any capital raise—whether via equity, debt, or other instruments—could impact shareholder value and dilute existing ownership.

• Growth and Business Operation Risks:

  The Company warns that its business may not grow as expected, or at all. Failure to achieve growth could result in continued losses. Success is heavily dependent on the widespread market acceptance of stem cell cryopreservation. Any shortfall in revenues, especially if accompanied by increased operating expenses, may have an immediate and material adverse impact on the Company’s financial results.

• Macroeconomic and Industry Risks:

  Cryo-Cell’s operations are exposed to global and regional economic conditions such as inflation, recession, higher interest rates, and currency fluctuations. These factors could reduce demand, increase credit risk, limit debt issuance, and reduce liquidity. The Company also faces rapid technological change in its sector, and regulatory hurdles could delay or halt new clinical trials and product introductions.

• Forward-Looking Statements:

  The Company’s report is filled with forward-looking statements, cautioning that actual results may differ significantly due to a variety of risks, including legal proceedings, the outcome of collaborative partnerships, and the success of product diversification and intellectual property portfolios.

Other Information

• Regulatory Compliance: Cryo-Cell confirms it is in compliance with all SEC reporting requirements and has not corrected any previously issued financial statements nor undergone restatements requiring recovery analysis of executive compensation.
• Legal Proceedings: The filing references ongoing and pending legal matters, which are identified as potential sources of uncertainty and risk for future performance.
• Executive Compensation and Governance: There are no new disclosures related to executive compensation or changes in corporate governance that would require specific shareholder action at the time of filing.

Conclusion

Overall, the most price-sensitive issues in this annual filing are the risks of delisting from NYSE American, the potential need for additional capital, and uncertainties regarding growth and regulatory challenges. Shareholders should closely monitor these factors, as any negative developments could have a material effect on the value and liquidity of their investment in Cryo-Cell International, Inc. The Company’s future performance remains highly dependent on market acceptance of its services, its ability to innovate and navigate regulatory challenges, and its capacity to maintain compliance with listing requirements and secure additional financing if needed.